ATE271040T1 - Substituierte pyridinderivate, deren herstellung und deren verwendung als modulatoren von acetylcholin-rezeptoren - Google Patents

Substituierte pyridinderivate, deren herstellung und deren verwendung als modulatoren von acetylcholin-rezeptoren

Info

Publication number
ATE271040T1
ATE271040T1 AT96913789T AT96913789T ATE271040T1 AT E271040 T1 ATE271040 T1 AT E271040T1 AT 96913789 T AT96913789 T AT 96913789T AT 96913789 T AT96913789 T AT 96913789T AT E271040 T1 ATE271040 T1 AT E271040T1
Authority
AT
Austria
Prior art keywords
disorders
disease
modulators
acetylcholine receptors
compounds
Prior art date
Application number
AT96913789T
Other languages
English (en)
Inventor
Nicholas D Cosford
Jean-Michel Vernier
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE271040T1 publication Critical patent/ATE271040T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT96913789T 1995-04-07 1996-04-04 Substituierte pyridinderivate, deren herstellung und deren verwendung als modulatoren von acetylcholin-rezeptoren ATE271040T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/419,597 US5585388A (en) 1995-04-07 1995-04-07 Substituted pyridines useful as modulators of acetylcholine receptors
PCT/US1996/005078 WO1996031475A2 (en) 1995-04-07 1996-04-04 Substituted pyridine derivatives, their preparation and their use as modulators of acetylcholine receptors

Publications (1)

Publication Number Publication Date
ATE271040T1 true ATE271040T1 (de) 2004-07-15

Family

ID=23662934

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96913789T ATE271040T1 (de) 1995-04-07 1996-04-04 Substituierte pyridinderivate, deren herstellung und deren verwendung als modulatoren von acetylcholin-rezeptoren

Country Status (9)

Country Link
US (3) US5585388A (de)
EP (1) EP0871615B1 (de)
JP (1) JP4138872B2 (de)
AT (1) ATE271040T1 (de)
AU (1) AU718517B2 (de)
CA (1) CA2217651A1 (de)
DE (1) DE69632916T2 (de)
ES (1) ES2224167T3 (de)
WO (1) WO1996031475A2 (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US20020052497A1 (en) * 2000-03-09 2002-05-02 Targacept, Inc. Compounds capable of activating cholinergic receptors
US6979695B2 (en) 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
US6437138B1 (en) 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
DE69717148T2 (de) * 1996-12-10 2003-10-02 Abbott Laboratories, Abbott Park 3-pyridylenantiomere und ihre verwendung als analgetika
US6133253A (en) * 1996-12-10 2000-10-17 Abbott Laboratories 3-Pyridyl enantiomers and their use as analgesics
US5861423A (en) * 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US5811442A (en) * 1997-02-21 1998-09-22 Bencherif; Merouane Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow
US6531606B1 (en) 1997-02-21 2003-03-11 Targacept, Inc. Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
EP1014974B1 (de) 1997-05-29 2004-08-11 H. Lundbeck A/S Behandlung der schizophrenie und der psychose
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6362009B1 (en) 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
MXPA00009619A (es) 1998-04-02 2006-03-09 Targacept Inc Composiciones farmaceuticas y metodos de uso.
WO1999051602A1 (en) * 1998-04-02 1999-10-14 R.J. Reynolds Tobacco Company Azatricyclo[3.3.1.1] decane derivatives and pharmaceutical compositions containing them
CA2709735A1 (en) * 1998-06-16 1999-12-23 Targacept, Inc. Aryl substituted olefinic amines and their use as cholinergic receptors agonists
US20050131034A1 (en) * 1998-06-16 2005-06-16 Caldwell William S. Compounds capable of activating cholinergic receptors
US6232316B1 (en) 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
US7790757B2 (en) * 1998-06-16 2010-09-07 Targacept, Inc. Compounds capable of activating cholinergic receptors
US6232326B1 (en) 1998-07-14 2001-05-15 Jodi A. Nelson Treatment for schizophrenia and other dopamine system dysfunctions
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
US6833370B1 (en) 1999-05-21 2004-12-21 Abbott Laboratories Heterocycle substituted aminoazacycles useful as central nervous system agents
KR100713572B1 (ko) * 1999-05-21 2007-05-02 아보트 러보러터리즈 중추 신경계 제제로서 유용한 헤테로사이클릭 치환된 아미노아자사이클 및 이를 포함하는 약제학적 조성물
WO2000071534A1 (en) * 1999-05-21 2000-11-30 Abbott Laboratories Heterocyclic substituted aminoazacycles useful as central nervous system agents
US20010031771A1 (en) 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
EP1185514A1 (de) * 1999-06-07 2002-03-13 Targacept, Inc. Pharmaceutische zusammensetzungen und verwendungsmethode
DE10005150A1 (de) 2000-02-07 2001-08-09 Merck Patent Gmbh Verfahren zur Herstellung von 5-Arylnicotinaldehyden
MY145722A (en) 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents
US6809105B2 (en) 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
US6458804B1 (en) 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
PL208787B1 (pl) * 2001-09-19 2011-06-30 Merck Patent Gmbh (2R, 4R/S)-2-({[5-(4-fluorofenylo)-pirydyn-3ylmetylo)]-amino}-metylo)-chroman-4-ol i (2R, 4R)-2-({[5-(4-fluorofenylo)-pirydyn-3ylmetylo)]-amino}-metylo)-chroman-4-ol, sposoby ich otrzymywania i zastosowanie do wytwarzania preparatów medycznych oraz zawierająca je kompozycja farmaceutyczna
HUP0501017A3 (en) * 2001-12-14 2010-06-28 Targacept Methods and compositions for treatment of central nervous system disorders
US7091357B2 (en) * 2001-12-26 2006-08-15 University Of Kentucky Research Foundation Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
DK1519939T5 (da) 2002-07-05 2011-01-24 Targacept Inc N-Aryl-diazaspirocykliske forbindelser og fremgangsmåder til fremstilling og anvendelse deraf
WO2004009775A2 (en) 2002-07-19 2004-01-29 Targacept, Inc. Methods and compositions relating to chimeric nicotinic receptor subunits
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
US7414055B2 (en) * 2003-04-24 2008-08-19 Merck & Co., Inc. Inhibitors of Akt activity
CN1809354A (zh) * 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
WO2005037832A2 (en) 2003-10-15 2005-04-28 Targacept, Inc. Azabicycyclic compounds for relieving pain and treating central nervous system disorders
ES2330849T3 (es) * 2004-04-02 2009-12-16 Arterial Remodelling Technologies Inc. Ensamblaje de stent basado en polimero.
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
CA2569654C (en) 2004-06-15 2010-12-21 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
AU2005266090A1 (en) 2004-07-23 2006-02-02 Pfizer Inc. Pyridine derivatives
CN101044134A (zh) 2004-09-20 2007-09-26 塔加西普特公司 具有烟碱性胆碱能受体活性的氮杂螺烯和氮杂螺烷化合物
UA88792C2 (ru) 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
US20090088433A1 (en) 2005-01-26 2009-04-02 Bertrand Leblond Methods of using as analgesics 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
ES2331153T3 (es) 2005-03-10 2009-12-22 Pfizer Inc. Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.
US7732607B2 (en) 2005-08-22 2010-06-08 Anatoly Mazurov Heteroaryl-substituted diazatricycloalkanes and methods of use thereof
US8017785B2 (en) 2006-05-09 2011-09-13 Astrazeneca Ab Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
TWI454262B (zh) 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
WO2008059370A2 (en) 2006-11-17 2008-05-22 Pfizer Japan Inc. Substituted bicyclocarboxyamide compounds
WO2008091588A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
TW200845977A (en) 2007-03-30 2008-12-01 Targacept Inc Sub-type selective azabicycloalkane derivatives
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
WO2009046025A1 (en) 2007-10-01 2009-04-09 Comentis, Inc. Quinuclidin-4-ylmethyl 1h-indole-3-carboxylate derivatives as alpha 7 nicotinic acetylcholine receptor ligands for the treatment of alzheimer's disease
AR072899A1 (es) 2008-08-07 2010-09-29 Merck Sharp & Dohme Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad.
MX2011004551A (es) * 2008-10-30 2011-05-25 Merck Sharp & Dohme Antagonistas del receptor de orexina de isonicotinamida.
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
TW201024283A (en) 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
WO2010065443A1 (en) 2008-12-01 2010-06-10 Targacept, Inc. Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
NZ596302A (en) 2009-05-15 2014-01-31 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
US8802694B2 (en) 2009-12-07 2014-08-12 Targacept, Inc. 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetycholine receptor ligands
CN103180277A (zh) 2010-05-20 2013-06-26 塔格塞普特股份有限公司 制备芳基取代的烯属胺的新方法
MX337106B (es) 2010-05-27 2016-02-12 Targacept Inc Antagonistas no competitivos de receptores nicotinicos.
WO2012125518A1 (en) 2011-03-14 2012-09-20 Targacept, Inc. Salt forms of 3 - cyclopropylcarbonyl - 3, 6 - diazabicyclo [3.1.1] heptane
WO2012129262A1 (en) 2011-03-23 2012-09-27 Targacept, Inc. Treatment of attention deficit/hyperactivity disease
TW201311698A (zh) 2011-08-22 2013-03-16 Targacept Inc 作為神經元菸鹼乙醯膽鹼受體配位體之１，４－二氮雜雙環［３．２．２］壬烷
JP2017524736A (ja) 2014-07-11 2017-08-31 アルファーマゲン，エルエルシー アルファ７−ニコチン性アセチルコリン受容体活性を調節するためのキヌクリジン化合物
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
CA3073212A1 (en) * 2017-09-19 2019-03-28 Merck Sharp & Dohme Corp. Heteroaryl allosteric modulators of nicotinic acetylcholine receptors
CN119775199B (zh) * 2025-02-21 2025-08-01 澳门科技大学 一种抗炎小分子化合物及其合成方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2194567A (en) * 1938-02-28 1940-03-26 Pyridium Corp Esters of aminopyridine carboxylic acid and processes for producing the same
GB945824A (en) * 1960-09-02 1964-01-08 Merck Ag E ªÏ-(pyridyl-3)-or ªÏ-(piperidyl-3)-propanol and derivatives thereof and processes for their manufacture
DE1231704B (de) * 1963-12-19 1967-01-05 Josef Klosa Dipl Chem Dr Rer N Verfahren zur Herstellung neuer Diaryl-alkylaminoverbindungen mit heterocyclischen Ringen
NL6401902A (de) * 1964-02-27 1965-08-30
US3313822A (en) * 1965-07-14 1967-04-11 Warner Lambert Pharmaceutical Diphenyl substituted aminoalkyl pyridines
SE361663B (de) * 1971-04-28 1973-11-12 Haessle Ab
LU65414A1 (de) * 1972-05-24 1973-12-04
FR2187317B2 (de) * 1972-06-07 1975-06-20 Hexachimie
US4009174A (en) * 1972-12-08 1977-02-22 The Boots Company Limited Esters of substituted nicotinic acids
DE2364685C3 (de) * 1973-12-27 1978-06-15 Beiersdorf Ag, 2000 Hamburg Phenoxyäthylamine
GB1485919A (en) * 1975-08-12 1977-09-14 Grindstedvaerket As Pyridine derivatives
FR2341311A1 (fr) * 1976-02-20 1977-09-16 Parcor Derives de la pyridoxine
JPS52125170A (en) * 1976-04-12 1977-10-20 Yoshitomi Pharmaceut Ind Ltd Pyridine derivatives
US4444774A (en) * 1982-07-29 1984-04-24 American Cyanamid Company 7-Heteroaryl[1,2,4]triazolo[1,5-a]pyrimidines
IL100688A (en) * 1987-08-01 1995-08-31 Takeda Chemical Industries Ltd Intermediates for the production of unsaturated amines in position A and the process for their preparation
IT1231477B (it) * 1989-07-12 1991-12-07 Sigma Tau Ind Farmaceuti (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
CA2029497C (en) * 1989-11-08 2002-06-04 Kunihiro Ninomiya (Deceased) 4-acylaminopyridine derivative
US5418229A (en) * 1990-01-06 1995-05-23 Alker; David Muscarinic receptor antagonists
DE4038335A1 (de) * 1990-12-01 1992-06-04 Boehringer Mannheim Gmbh Neue pyridinderivate, verfahren zu ihrer herstellung und verwendung als arzneimittel
US5212188A (en) * 1992-03-02 1993-05-18 R. J. Reynolds Tabacco Company Method for treatment of neurodegenerative diseases
US5214060A (en) * 1992-04-10 1993-05-25 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5232932A (en) * 1992-05-21 1993-08-03 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
DE4232561A1 (de) * 1992-09-29 1994-03-31 Bayer Ag Bekämpfung von Fischparasiten
IL107184A (en) * 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
DE69333527T2 (de) * 1993-02-23 2005-06-16 Brigham & Women's Hospital, Inc., Boston Calciumrezeptoraktive moleküle

Also Published As

Publication number Publication date
US5686473A (en) 1997-11-11
JP4138872B2 (ja) 2008-08-27
US5736560A (en) 1998-04-07
EP0871615A1 (de) 1998-10-21
DE69632916D1 (de) 2004-08-19
WO1996031475A3 (en) 1997-02-06
AU718517B2 (en) 2000-04-13
EP0871615B1 (de) 2004-07-14
AU5663696A (en) 1996-10-23
ES2224167T3 (es) 2005-03-01
CA2217651A1 (en) 1996-10-10
US5585388A (en) 1996-12-17
JPH11503430A (ja) 1999-03-26
WO1996031475A2 (en) 1996-10-10
DE69632916T2 (de) 2005-07-14

Similar Documents

Publication Publication Date Title
DE69632916D1 (de) Substituierte Pyridinderivate, deren Herstellung und deren Verwendung als Modulatoren von Acetylcholin-Rezeptoren
ATE248160T1 (de) Pyridin acetylcholin-rezeptor-modulatoren
ATE240942T1 (de) Neue substituierte aryl-verbindungen als acetylcholine receptors modulatoren
DE69528823D1 (en) Morpholinwirkstoffvorläufer als tachykininreceptorantagonisten
MX9706969A (es) 3-(1,2,3,6-tetrahidropiridin-4-il)-1h-indoles y 3-(piperidin-4-il)-1h-indoles sustituidos en la posicion 5: agonistas del 5-ht1f novedosos.
DE69616480D1 (de) Piperidinderivate als neurokininantagonisten
NO940927L (no) Kondenserte tricykliske nitrogenholdige heterocykler som substans-P-reseptor-antagonister
NO963785L (no) Fremgangsmåte for behandling av 5HT2B-reseptor-relaterte betingelser
AU1856397A (en) Heterocyclic derivatives as antidiabetic and antiobesity agents
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
RU94046364A (ru) Замещенные гетероциклы, способ их получения, фармокомпозиция, способ лечения
DE69737683D1 (de) Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
AU2115997A (en) Antidiabetic agents
EP0835869A3 (de) Serotonin-5-HT1F-Rezeptor Agoniste
ATE245632T1 (de) Benzodiazepin derivate verwendbar als cck- rezeptoren antagonisten
DK0789697T3 (da) Krystalform af vandfrit 7-([1alfa, 5alfa, 6alfa,]-6-amino-3-azabicyclo[3.1.0]hex-3-yl)-6-fluor-1-(2,4-difluorphenyl)-1,4-d
WO2000027379A3 (en) Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
ATE178886T1 (de) 1-aryl-2-acylamino-ethan-verbindungen und ihre verwendung als neurokinin- insbesondere als neurokinin-1-antagonisten
CA2168131A1 (en) Tetrahydro-1h-benzazepinones containing acid surrogates
NO961333L (no) Nye pyrazolderivater som angiotensin-II-antagonister
PL297472A1 (en) Benzimidazoles, therapeutic agents containing such compounds and method of obtaining them
CA2336009A1 (en) Use of receptors of the rev-erb family to screen substances which are useful in the treatment of lipid metabolism dysfunctions
ATE43610T1 (de) Acino-foetale differenzierungsproteine verbunden mit krebs des pankreas, antiserum und monoklonale antikoerper gegen diese proteine und verfahren zu ihrer herstellung.
CS53688A2 (en) Method of new substituted 3-phenyl-7h-thiazolo/3,2-b//1,2,4/triazine -7-ons production
DK0923549T3 (da) Methansulfonatsalt af et arylpiperazin afledt af tryptamin og solvater deraf til farmaceutisk anvendelse

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties